GILUPI and SCIENION announce Collaboration for the Development of Single-Cell CTC Analysis
GILUPI GmbH and SCIENION AG announced that the companies intend to intensify their collaboration in the field of single circulating tumor cell (CTC) analysis. CTCs are rare cells that can be found in the peripheral blood of cancer patients, often causing metastasis. Their potential in the diagnosis and treatment of cancer has initiated worldwide research towards new methods for the separation and detection of CTCs from whole blood.
GILUPI is the manufacturer of the GILUPI CellCollector®, the first CE labeled medical device for in vivo CTC collection, whereas SCIENION has developed the cellenONE® dispensing technology for low volume and high accuracy single cell isolation and dispensing. The companies believe that a combination of both technologies will create a reliable and efficient workflow from patient to result.
Dr. Holger Eickhoff, CEO of SCIENION AG points out: “Efficient isolation of rare cells combined with highly accurate dispensing is the foundation for molecular profiling of metastasis causing CTCs. GILUPI is one of the pioneers in enriching CTCs and we see a strong synergy in combining both technologies.”
Dr. Christian Jurinke, CEO of GILUPI GmbH comments: “We believe that molecular analysis of single CTCs is an important cornerstone of advanced and personalized cancer treatment. The technology of SCIENION is very well suited to enable molecular profiling of CTCs on a single cell level once they are isolated from the patients.”
Under this collaboration, the companies intend to develop a workflow that allows for the isolation of CTCs directly from the bloodstream of the patient and efficiently decollates them for single cell downstream molecular analysis such as next-generation sequencing, genotyping or digital PCR. The results can then be used in determining the drug response and to provide guidance on therapy.
Volmerstraße 7b; D-12489 Berlin
Phone: +49 (0)30 - 6392 1700